Liraglutide Injection — FDA Drug Shortage

To Be Discontinued — Novo Nordisk, Inc.

The FDA lists a drug shortage record for Liraglutide Injection (injection) from Novo Nordisk, Inc. with status To Be Discontinued. The shortage was first posted on 08/25/2026.

Shortage Details

Status
To Be Discontinued
Company
Novo Nordisk, Inc.
Package NDC
0169-2800-15
Dosage Form
Injection
Presentation
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Initial Posting
08/25/2026
Revised Date